Nautilus Biotechnology (NAUT) CFO awarded 160,000 service-based stock options

Rhea-AI Filing Summary

Nautilus Biotechnology reported that its CFO and Treasurer, Anna Mowry, received a grant of stock options covering 160,000 shares of common stock. The options were awarded at an exercise price of $0.00 per share, reflecting a compensatory grant rather than an open-market purchase.

According to the award’s vesting terms, 25% of the options will vest on the one-year anniversary of the vesting commencement date of January 1, 2026, with the remaining shares vesting in equal monthly installments over the following 36 months, contingent on her continued service as a “Service Provider.”

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mowry Anna

(Last) (First) (Middle)

C/O NAUTILUS BIOTECHNOLOGY, INC.

2701 EASTLAKE AVENUE EAST

(Street)

SEATTLE WA 98102

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nautilus Biotechnology, Inc. [ NAUT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO and Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.32	03/02/2026		A		160,000		(1)	03/02/2036	Common Stock	160,000	$0	160,000	D

Explanation of Responses:

1. Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2026.

Remarks:

	/s/ Mathew B. Murphy, as Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Nautilus Biotechnology (NAUT) report for Anna Mowry?

Nautilus Biotechnology reported that CFO and Treasurer Anna Mowry received a grant of stock options for 160,000 shares. These options were awarded as compensation, not bought on the open market, and give her the right to purchase company stock under specified vesting terms.

How many stock options did NAUT’s CFO receive in this Form 4 filing?

The CFO of Nautilus Biotechnology received stock options covering 160,000 shares of common stock. This award increases her potential future ownership if the options vest and are exercised, aligning part of her compensation with the company’s long-term equity performance and shareholder interests.

What are the vesting terms of the Nautilus Biotechnology (NAUT) CFO’s stock options?

The stock options vest over time, starting from a vesting commencement date of January 1, 2026. Twenty-five percent vest on the first anniversary of that date, with the remaining shares vesting monthly in equal installments over the next 36 months, subject to continued service.

Is the NAUT CFO’s option grant an open-market stock purchase?

No, the Nautilus Biotechnology CFO’s transaction is a grant of stock options, not an open-market stock purchase. The Form 4 describes it as a grant or award, with an exercise price of $0.00 per share at grant, tied to ongoing service-based vesting conditions.

When does vesting begin for the Nautilus Biotechnology (NAUT) CFO’s stock options?

Vesting for the CFO’s stock options begins from a vesting commencement date of January 1, 2026. A quarter of the options vest on the first anniversary of that date, and the rest vest in equal monthly installments over the following three years, assuming continued service.